These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7118063)

  • 1. Effects of thirsting on biological half-life and organ distribution of 3H-dDAVP in rat.
    Janáky T; László FA; Baláspiri L; Morgat JL
    Horm Metab Res; 1982 Jul; 14(7):385-6. PubMed ID: 7118063
    [No Abstract]   [Full Text] [Related]  

  • 2. Biological half-lives and organ distribution of tritiated 8-lysine-vasopressin and 1-deamino-8-D-arginine-vasopressin in Brattleboro rats.
    Janáky T; Laczi F; László FA
    Ann N Y Acad Sci; 1982; 394():116-27. PubMed ID: 6960751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological half-life and organ distribution of [3H]1-deamino-8-D-arginine-vasopressin in the rat.
    László FA; Janáky T; Baláspiri L; Morgat JL
    J Endocrinol; 1981 Feb; 88(2):181-6. PubMed ID: 7205124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tritiation of vasopressin analogues and their metabolic fate after intravenous injection in the rat.
    Janáky T; László FA; Morgat JL
    Acta Med Hung; 1984; 41(1):43-54. PubMed ID: 6739223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DDAVP (1-desamino-8-D-arginine vasopressin) clearance rate.
    Stegner H; Artman HG; Leake RD; Fisher DA
    Acta Endocrinol (Copenh); 1984 Oct; 107(2):204-6. PubMed ID: 6495988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of 1-desamino-8-D-arginine vasopressin (DDAVP) in patients with central diabetes insipidus.
    Pullan PT; Burger HG; Johnston CI
    Clin Endocrinol (Oxf); 1978 Sep; 9(3):273-8. PubMed ID: 709897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impermeability of the blood-cerebrospinal fluid barrier to 1-deamino-8-D-arginine-vasopressin (DDAVP) in patients with acquired, communicating hydrocephalus.
    Sørensen PS; Vilhardt H; Gjerris F; Warberg J
    Eur J Clin Invest; 1984 Dec; 14(6):435-9. PubMed ID: 6441719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological half-life and organ distribution of [3H]8-arginine-vasopressin in the rat.
    Janáky T; László FA; Sirokmán F; Morgat JL
    J Endocrinol; 1982 Jun; 93(3):295-303. PubMed ID: 7086324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of infused arginine-vasopressin and its long-acting deaminated analogue in rats.
    Gazis D; Sawyer WH
    J Endocrinol; 1978 Aug; 78(2):179-86. PubMed ID: 702013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of three specific radioimmunoassays in measuring neurohypophysial hormone content and plasma concentrations of vasopressin, oxytocin and DDAVP in rats after prolonged infusion of DDAVP.
    Lundin S; Melin P; Vilhardt H
    Experientia; 1985 Jul; 41(7):933-5. PubMed ID: 4007132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma concentrations of 1-deamino-8-D-arginine vasopressin after intragastric administration in the rat.
    Lundin S; Melin P; Vilhardt H
    Acta Endocrinol (Copenh); 1985 Feb; 108(2):179-83. PubMed ID: 3969814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Degradation of [mercaptopropionic acid1, D-arginine8]-vasopressin (dDAVP) in pancreatic juice and intestinal mucosa homogenate.
    Lundin S; Bengtsson HI; Folkesson HG; Weström BR
    Pharmacol Toxicol; 1989 Aug; 65(2):92-5. PubMed ID: 2813288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of uPA release in human peripheral blood lymphocytes by [deamino-Cysl,D-Arg8]-vasopressin (dDAVP).
    Yamaguchi Y; Yamada K; Suzuki T; Wu YP; Kita K; Takahashi S; Ichinose M; Suzuki N
    Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E970-6. PubMed ID: 15198931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological half-life and organ distribution of [3H]8-arginine vasopressin following administration of vasopressin receptor antagonist OPC-31260.
    Molnár AH; Varga C; Janáky T; Tóth G; Tóth G; Farkas J; László F; László FA
    Regul Pept; 2007 Jun; 141(1-3):12-8. PubMed ID: 17258819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Light microscopic autoradiographic visualization of [3H]-arginine vasopressin binding sites in rat brain.
    Yamamura HI; Gee KW; Brinton RE; Davis TP; Hadley M; Wamsley JK
    Life Sci; 1983 Apr; 32(16):1919-24. PubMed ID: 6300592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance of 1-deamino-[8-D-arginine]-vasopressin to in vitro degradation as compared with arginine vasopressin.
    Matsui K; Kimura T; Ota K; Iitake K; Shoji M; Inoue M; Yoshinaga K
    Endocrinol Jpn; 1985 Aug; 32(4):547-57. PubMed ID: 3936702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of thirsting on the biological half-life and organ-distribution of 3H-lysin vasopressin.
    László FA; Nagy E; Gáspár L; Kéri G; Teplán I
    Horm Metab Res; 1980 Sep; 12(9):471-5. PubMed ID: 7429417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Properties of [3H]1-desamino-8-D-arginine vasopressin as a radioligand for vasopressin V2-receptors in rat kidney.
    Marchingo AJ; Abrahams JM; Woodcock EA; Smith AI; Mendelsohn FA; Johnston CI
    Endocrinology; 1988 Apr; 122(4):1328-36. PubMed ID: 2964362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor.
    Saito M; Tahara A; Sugimoto T
    Biochem Pharmacol; 1997 Jun; 53(11):1711-7. PubMed ID: 9264324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel ligand specificity of pituitary vasopressin receptors in the rat.
    Antoni FA
    Neuroendocrinology; 1984 Aug; 39(2):186-8. PubMed ID: 6089020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.